ALLOGENE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.76 USD | -3.50% |
|
-10.10% | -14.02% |
Presenter SpeechJason Gerberry (Analysts)Thanks for joining us this morning at the Bank of Ame...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on four core programs: Large B-Cell Lymphoma (LBCL), Chronic Lymphocytic Leukemia (CLL), Autoimmune Disease and Renal Cell Carcinoma. It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL and CLL. Its pipeline also includes ALLO-316, ALLO-329 and ALLO-647.
Calendar
2024-05-12
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
2.76
USD
Average target price
11.66
USD
Spread / Average Target
+322.40%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -14.02% | 471M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- ALLO Stock
- News Allogene Therapeutics, Inc.
- Transcript : Allogene Therapeutics, Inc. Presents at Bank of America 2022 Healthcare Conference, May-10-2022 08
